Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Q1 2019 Earnings Presentation
19 slides from Trendlines's earnings presentation, May 13, 2019
Slide 1: The Trendlines Group Financial Highlights Q1 2019
The Trendlines Group Financial Highlights Q1 2019 Steve Rhodes Todd Dollinger Haim Brosh Chairman and CEO Chairman and CEO Chief Financial Officer 13 May 2019 SGX:42T OTCQX: TRNLY
Slide 2: Agenda
Agenda • Corporate highlights • Financial highlights • Post Q1 2019 developments 2
Slide 3: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 4: Corporate highlights
Corporate highlights
Slide 5: 12 years of portfolio value expansion
12 years of portfolio value expansion Note: Portfolio value does not reflect 6 Singapore-based companies due to US$ millions consolidation Portfolio value with exit proceeds 140 120 Portfolio value* 100 (excluding consolidated subsidiaries) 80 60 40 20 0 31.12.08 31.12.09 31.12.10 31.12.11 31.12.12
Slide 6: Key financial developments Q1 2019
Key financial developments Q1 2019 31 March 2019 31 December 2018 Change Portfolio value US$ 97.5 million US$ 97.2 million US$ 0.3 million Book value US$ 85.8 million US$ 86.4 million - US$ 0.6 million Current assets US$ 9.7 million US$ 11.8 million - US$ 2.1 million Q1 2019 Q1 2018 Change Total G&A
Slide 7: Key corporate developments Q1 2019
Key corporate developments Q1 2019 • Ongoing development of Agrifood Innovation Centre in Singapore • Focus on value-building of existing portfolio companies and establishment of fewer new companies reflected in management changes and updates • Continued monitoring of cash and adjustments as needed
Slide 8: Portfolio company achievements
Portfolio company achievements • Vessi Medical Ltd. announced successful animal trial • ZygoFix Ltd. received Horizon 2020 grant • Leviticus Cardio Ltd. announced successful first in human procedure • Stimatix GI Ltd. product launch continues under Be 1® brand • Omeq Medical Ltd. completed $3 millio
Slide 9: Financial highlights
Financial highlights
Slide 10: Consolidated condensed report of income
Consolidated condensed report of income CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME U.S. dollars in thousands, except share data 3 months ended 31 March 2019 2018 Income Loss from change in fair value of investments in Portfolio (252) (1,234) Companies Income from servic
Slide 11: Consolidated condensed report of income
Consolidated condensed report of income CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME U.S. dollars in thousands, except share data 3 months ended 31 March 2019 2018 Expenses Operating, general and administrative expenses 1,447 1,507 Marketing expenses 49 95 R&D expenses, n
Slide 12: Key value components
Key value components Change in portfolio value during Q1 2019 Balance sheet as at 31 March 2019 (US$ millions) 1.5 (1.3) 9.7 (3.1) (3.9) (13.6) (0.8) 97.2 97.5 85.8 Net portfolio Investments Fair value Net portfolio Cash, short- Fair value of Deferred Deferred tax** Payables & Total equity value 31.
Slide 13: Stock performance: Net Asset Value (NAV)
Stock performance: Net Asset Value (NAV)* NAV* SGD USD Per share S$ 0.19 Per ADR US$ 7.0 % discount to NAV 53% *As at 31 March 2019 Discount to NAV SGD Price per share** S$ 0.089 % discount to NAV 53% **As at 7 May 2019 13
Slide 14: Stock performance: Trendlines vs. Catalist trends
Stock performance: Trendlines vs. Catalist trends 12-month Trendlines vs Catalist Index Trend 500 16 450 14 400 12 350 FTSE ST Catalist Index 10 300 Trendlines’ price per share 250 8 200 6 150 4 100 2 50 0 0 3.5.18 1.6.18 2.7.18 1.8.18 3.9.18 1.10.18 1.11.18 3.12.18 2.1.19 1.2.19 1.3.19 1.4.19 2.5.1
Slide 15: Post Q1 2019 developments
Post Q1 2019 developments
Slide 16: Post Q1 2019 developments
Post Q1 2019 developments • Stimatix GI Ltd. declared dividend to shareholders, including Trendlines • ApiFix Ltd. closed Series B financing round and named a winner in MedTechInnovator Pediatric Pitch Event • STStent Ltd. completed successful feasibility study of its ArchSinus device as part of an
Slide 17: Looking ahead: Trendlines Agrifood Fund
Looking ahead: Trendlines Agrifood Fund US$40 million agrifood tech-focused venture fund • Will employ a blended early/late-stage investment strategy to • achieve early exits • attain IRR of at least 20% Singapore Government Support Trendlines Group VP Nitza Kardish, PhD, • Prominent Singapore inves
Slide 18: AgriVest, September 2019, Tel Aviv
AgriVest, 24 September 2019, Tel Aviv 18
Slide 19: SGX: 42T OTCQX: TRNLY www.trendlines.com
SGX: 42T Steve Rhodes, Chairman & CEO OTCQX: TRNLY steve@trendlines.com Todd Dollinger, Chairman & CEO +972.72.260.7000 todd@trendlines.com www.trendlines.com Haim Brosh, Chief Financial Officer haim@trendlines.com 13 May 2019